Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Natural killer (NK) cells are enriched within the liver. Apart from conventional NK (cNK) cells, recent studies identified a liver-resident NK (LrNK) subset, which constitutes about half of hepatic NK cells and exhibits distinct developmental, phenotypic, and functional features. However, it remains unclear whether and how LrNK cells, as well as cNK cells, participate in the development of hepatocellular carcinoma (HCC) individually. Here, we report that both LrNK and cNK cells are significantly decreased in HCC. The T-cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) was significantly upregulated in both tumor-infiltrating LrNK and cNK cells and suppressed their cytokine secretion and cytotoxic activity. Mechanistically, phosphatidylserine (PtdSer) engagement promoted phosphorylation of Tim-3, which then competed with PI3K p110 to bind p85, inhibiting downstream Akt/mTORC1 signaling and resulting in malfunctioning of both NK-cell subsets. Tim-3 blockade retarded HCC growth in a NK-cell–dependent manner. These studies for the first time report the presence and dysfunction of LrNK cells in HCC and show that Tim-3–mediated PI3K/mTORC1 interference is responsible for the dysfunction of both tumor-infiltrating cNK and LrNK cells, providing a new strategy for immune checkpoint-based targeting. Significance: Tim-3 enhances hepatocellular carcinoma growth by blocking natural killer cell function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nevertheless, the binding of TIM‐3 to PS in NK cells abrogated the activity and all‐inclusive cytokines production [315].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [315]
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Zhang, Q., Bi, J., Zheng, X., Chen, Y., Wang, H., Wu, W., Wang, Z., Wu, Q., Peng, H., Wei, H., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0132-0 · Cited by 1,122
Self-citationKlose, C. S. N., Flach, M., Möhle, L., Rogell, L., Hoyler, T., Ebert, K., Fabiunke, C., Pfeifer, D., Sexl, V., Fonseca-Pereira, D., et al. (2014) · Cell · doi:10.1016/j.cell.2014.03.030 · Cited by 1,080
Tim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
Self-citationMaturation of mouse NK cells is a 4-stage developmental program
Chiossone, L., Chaix, J., Fuseri, N., Roth, C., Vivier, E., & Walzer, T. (2009) · Blood · doi:10.1182/blood-2008-10-187179 · Cited by 787
Cited by
Ho, D. W.-H., Tsui, Y.-M., Chan, L.-K., Sze, K. M.-F., Zhang, X., Cheu, J. W.-S., Chiu, Y.-T., Lee, J. M.-F., Chan, A. C.-Y., Cheung, E. T.-Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24010-1 · Cited by 324
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
Giraud, J., Chalopin, D., Blanc, J.-F., & Saleh, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655697 · Cited by 221
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy
Gaikwad, S. R., Agrawal, M. Y., Kaushik, I., Ramachandran, S., & Srivastava, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.014 · Cited by 172
Yin, Y., Feng, W., Chen, J., Chen, X., Wang, G., Wang, S., Xu, X., Nie, Y., Fan, D., Wu, K., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00539-x · Cited by 137
“TIM-3 is upregulated on NK cells in HCC, blocking cytokine secretion and cytotoxicity through a PI3K/Akt/mTOR-dependent way [267].”
Background
Metadata
- Authors
- Tan, S., Xu, Y., Wang, Z., Wang, T., Du, X., Song, X., Guo, X., Peng, J., Zhang, J., Liang, Y., Lu, J., Peng, J., Gao, C., Wu, Z., Li, C., Li, N., Gao, L., Liang, X., & Ma, C.
- Affiliations
- Shandong University (CN)
- Karolinska University Hospital (SE)
- Corresponding author
- Liang, Xiaohong
- Ma, Chunhong
- ORCID
- Venue
- Cancer Research
- Published
- 2020-03-01
- Volume
- 80
- Issue
- 5
- Pages
- 1130-1142
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2995834723
- Cited by
- 147
- References
- 41
- Citations by year
- 2026: 12 · 2025: 26 · 2024: 22 · 2023: 23 · 2022: 30 · 2021: 27 · 2020: 7
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation of China (81830017, 81672425, 31600714)
- National Key Research and Development Program (2016YFE0127000, 2018YFE0126500)
- National Natural Science Fund for Outstanding Youth Fund (81425012)
- Key Research & Development Plan of Shandong Province (2016ZDJS07A17, 2018YFJH0503, 2017GSF18185)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- TIM-3, natural killer cells, conventional NK cells, hepatocellular carcinoma, PI3K signaling, mTORC1, Akt signaling, phosphatidylserine, tumor-infiltrating immune cells, NK cell dysfunction, immune checkpoint blockade, tumor surveillance
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Mechanistic Target of Rapamycin Complex 1, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Female, Hepatectomy, Carcinoma, Hepatocellular, Humans, Killer Cells, Natural, Liver, Liver Neoplasms, Male, Middle Aged, Phosphatidylserines, Phosphorylation, Signal Transduction, Up-Regulation, Mice, Knockout, Tumor Escape, Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling. https://app.cochat.ai/papers/10.1158/0008-5472.can-19-2332
- The paper
- Tan, S., Xu, Y., Wang, Z., Wang, T., Du, X., Song, X., Guo, X., Peng, J., Zhang, J., Liang, Y., Lu, J., Peng, J., Gao, C., Wu, Z., Li, C., Li, N., Gao, L., Liang, X., & Ma, C. (2020). Tim-3 Hampers Tumor Surveillance of Liver-Resident and Conventional NK Cells by Disrupting PI3K Signaling. Cancer Research. https://doi.org/10.1158/0008-5472.can-19-2332
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.